Therapeutic approaches to reflux disease, focusing on acid secretion

Journal of Gastroenterology

Volumn 38, Issue SUPPL. 15, 2003, Pages 13-19

  Kinoshita, Yoshikazu ^a   Adachi, Kyoichi ^a   Fujishiro, Hirofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

H2 receptor antagonist; Helicobacter pylori; Proton pump inhibitor

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ANTACID AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CISAPRIDE; CYTOCHROME P450 2C19; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; NON PRESCRIPTION DRUG; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERANCE; ENDOSCOPIC SURGERY; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NIGHT; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH PH; TREATMENT INDICATION;

ANTACIDS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMPS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037255960     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Grande L, Lacima G, Ros E, Pera M, Ascaso C, Visa J, et al. Deterioration of esophageal motility with age: a manometric study of 79 healthy subjects. Am J Gastroenterol 1999;94:1795-801.
2. Deprez P, Fiasse R. Healing of severe esophagitis improves esophageal peristaltic dysfunction. Dig Dis Sci 1999;44:125-33.
3. Amano K, Adachi K, Katsube T, Watanabe M, Kinoshita Y. Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol 2001;16:132-6.
4. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997;41:452-8.
5. Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 yeas in Japan. Am J Gastroenterol 1999;24:2094-9.
6. Riber C, Wojdemann M, Bisgaard T, Ingels H, Rehfeld JF, Olsen O. Fish oil reduces gastric acid secretion. Scand J Gastroenterol 1999;34:845-8.
7. al-Harbi MM, Islam MW, al-Shabanah OA, al-Gharably NM. Effect of acute administration of fish oil (omega-3 marine triglyceride) on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats. Food Chem Toxicol 1995:33:553-8.
8. Freston JW, Asaka M, Chiba T, Howden CW, Hunt RH, Sugano K, et al. Acid-related disorders in the new millennium: European, Japanese and North American perspectives. Eur J Gastroenterol Hepatol 1998;10(suppl 2):S1-40.
9. Filipi CJ, Lehman GA, Rothstein RI, Raijman I, Stiegmann GV, Waring JP, et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc 2001;53:416-22.
10. Martinez-Serna T, Davis RE, Mason R, Perdikis G, Filipi CJ, Lehman G, et al. Endoscopic valvuloplasty for GERD. Gastrointest Endosc 2000;52:663-70.
11. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000;118:7-13.
12. Trudgill NJ, Hussain FN, Moustafa M, Ajjan R, D'Amato M, Riley SA. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Aliment Pharmacol Ther 2001;15:1357-64.
13. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
14. Khoury RM, Katz PO, Castell DO. Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment Pharmacol Ther 1999;13:1211-4.
15. Hurlimann S, Abbuhl B, Inauen W. Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994;8:193-201.
16. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 says of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-89.
17. Katsube T, Adachi K, Ono M, Kawamura A, Yuki M. Fujishiro H, et al. Usefulness of PPI test with rabeprazole for the diagnosis of symptomatic GERD. Jpn J Clin Exp Med 2001;78:1721-4.
18. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
19. Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000;14:1049-56.
20. Peghini PL, Katz PO, Bracy NA. Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-7.
21. van Herwaarden MA, Samson M, Smout AJ. Helicobacter pylori eradication increases nocturnal acid breakthrough. Aliment Pharmacol Ther 2000;14:961-2.
22. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, Perez-Perez GI, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000;95:2206-11.
23. Loffeld RJ, Werdmuller BF, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000;62:95-9.
24. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999;34:553-9.
25. Fujishiro H, Adachi K, Kawamura A, Katsube T, Ono M, Kinoshita Y, et al. Influence of Helicobacter pylori infection on the prevalence of reflex esophagitis in Japanese patients. J Gastroenterol Hepatol 2001;16:1217-21.
26. Johnsson L, Adlouni W, Johnsson F, Joelsson B. Timing of reflux symptoms and esophageal acid exposure. Gullet 1992;2:58-62.
27. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kinoshita Y, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001;16:1191-6.
28. Adachi K, Kinoshita Y. Gastric acid secretion in the cases with refractory reflux esophagitis (in Japanese). Shokakika 2001;32: 144-52.
29. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M. et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65:552-61.
30. Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001;36: 669-72.
31. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(suppl 3):27-36.
32. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Kinoshita Y, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000;14:1259-66.
33. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999;13:1611-20.
34. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
35. Netzer P, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999;94:351-7.
36. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000;95:57-61.
37. Maekawa T, Kinoshita Y, Okada A, Fukui H, Waki S, Hassan S, et al. Relationship between severity and symptoms of reflux oesophagitis in elderly patients in Japan. J Gastroenterol Hepatol 1998;13:927-30.
38. 2RA do not provide sustained suppression of nocturnal acid breakthrough. Gastroenterology 2001;120(suppl 1):A33.
39. 2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther 1993;264:152-7.
40. Goldin GF, Marcinkiewicz M, Zbroch T, Bityutskiy LP, McCallum RW. Sarosiek J. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. Dig Dis Sci 1997;42:1362-9.
41. Adachi K, Ono M, Kawamura A, Yuki M, Fujishiro H, Kinoshita Y. Nizatidine and cisapride enhance salivary secretion in humans. Aliment Pharmacol Ther 2002;16:297-301.
42. Brown CM, Rees WD. Review article: factors protecting the esophagus against acid-mediated injury. Aliment Pharmacol Ther 1995;9:251-62.